Correspondence
==============

We write in response to the report by Charles Feldman and Ronald Anderson about the recent advances in the understanding of *Streptococcus pneumoniae* infections ^[@ref-1]^.

While this article provided an informative and complete review of the current burden of the disease, pathogenesis and therapeutic options, we have noted a significant omission in the chapter dealing with available immunization strategies, which did not mention the WHO prequalified Pneumococcal Nontypeable *Haemophilus influenzae* Protein D Conjugate Vaccine (PHiD-CV; GSK Vaccines, Belgium). This vaccine is currently licensed in more than 125 countries with more than 200 million doses distributed as of August 2014 and is used in vaccination programmes in more than 40 countries or regions.

We feel it is important that health care professionals are made aware of the available evidence supporting the use of this vaccine in order that they are able to make an informed choice about the best care for their patients, and therefore we provide additional information to supplement the review article. It is the only modern pneumococcal conjugate vaccine with impact on invasive pneumococcal disease, pneumonia and acute otitis media that has been proven in two pivotal randomized controlled efficacy trials performed in Finland and Latin America ^[@ref-2]--\ [@ref-4]^. Thanks to its world-wide use, there is also a plethora of post-marketing and epidemiology data spanning five continents, recently reviewed by Plosker ^[@ref-8]^, that proves its impact on the pneumococcal disease and makes it a worth-while alternative to the pneumococcal conjugate vaccine PCV13 which the health care community should be made aware of ^[@ref-5]--\ [@ref-7]^. We have summarized the main effectiveness and impact data in [Table 1](#T1){ref-type="table"}.

###### Summary of the main effectiveness and impact data of PHiD-CV.

IPD: Invasive Pneumococcal disease; VE: vaccine efficacy; RR: relative rate reduction.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Randomized Clinical Trials                                                                                                                                
  ------------------------------------------------------------------- ------------------------------------------- ----------------------------------------- ---------------------------------------
  Finland                                                             Vaccine serotype - 3+1\                     X                                         X
                                                                      **VE=100%** (95%CI : 83, 100) ^[@ref-2]^\                                             
                                                                      \                                                                                     
                                                                      Vaccine serotype - 2+1\                                                               
                                                                      **VE=92%** (95% CI: 58, 100) ^[@ref-2]^                                               

  Any Serotype - 3+1/2+1\                                             X                                           **VE=44%** (95% CI: 24, 59) ^[@ref-4]^    
  **VE=93%** (95% CI: 75, 99) ^[@ref-2]^                                                                                                                    

  Latin America                                                       Vaccine serotype - 3+1\                     Vaccine serotype\                         **VE=26%** (95% CI: 8, 40) ^[@ref-3]^
                                                                      **VE=100%** (95% CI: 77, 100) ^[@ref-3]^\   **VE=70%** (95% CI: 30, 87) ^[@ref-3]^\   
                                                                      \                                           \                                         
                                                                      Any Serotype - 3+1\                         Clinical Diagnosed\                       
                                                                      **VE=67%** (95% CI: 22, 86) ^[@ref-3]^      **VE=19%** (95% CI: 4, 31) ^[@ref-3]^     

  **Impact and surveillance data on Invasive Pneumococcal Disease**                                                                                         

  Quebec (case-\                                                      Vaccine-type (+6A)\                                                                   
  controlled study)                                                   VE=99% (95% CI: 79, 100) ^[@ref-5]^\                                                  
                                                                      \                                                                                     
                                                                      19A IPD\                                                                              
                                                                      **VE=67%** (95% CI: 8, 88) ^[@ref-5]^\                                                
                                                                      \                                                                                     
                                                                      All IPD\                                                                              
                                                                      **VE=75%** (95% CI: 53, 79) ^[@ref-5]^                                                

  Brazil (case-\                                                      Vaccine type\                                                                         
  controlled study)                                                   **VE=84%** (95% CI: 66, 92) ^[@ref-6]^\                                               
                                                                      \                                                                                     
                                                                      19A\                                                                                  
                                                                      **VE=82%** (95% CI: 11, 96) ^[@ref-6]^                                                

  Finland (time\                                                      Vaccine type\                                                                         
  series analysis)                                                    **RR=92%** (95% CI: 85, 96) ^[@ref-7]^\                                               
                                                                      \                                                                                     
                                                                      19A\                                                                                  
                                                                      **RR=77%** (95% CI: 41, 93) ^[@ref-7]^\                                               
                                                                      \                                                                                     
                                                                      All IPD\                                                                              
                                                                      **RR=80%** (95% CI: 72, 86) ^[@ref-7]^                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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The correspondence article *"Further available immunization option to prevent pneumococcal disease"* from Vojtek & Hoet provides relevant information regarding one of the currently available pneumococcal conjugate vaccines. This information was missing in the review article (Recent advances in our understanding of *Streptococcus pneumoniae* infection ) written by Feldman & Anderson. 

The correspondence article is well written and should be considered for indexing.

I have only minor comments: In the second paragraph, when mentioning that the PHiD-CV vaccine is currently licensed in more than 125 countries, the authors should make clear that the vaccine **is licensed** **for active immunization against invasive disease, pneumonia, and acute otitis media (AOM) caused by *S. pneumoniae* in infants and young children up to 5 years of age**.In the third paragraph, when mentioning that the PHiD-CV vaccine is a worth-while alternative to the pneumococcal conjugate vaccine PCV13, the authors should add: ... **in children younger than 5 years of age**.In Table 1, when showing the different study results observed with the PHiD-CV vaccine, **the authors should specify which results are vaccine efficacy data and which are vaccine effectiveness data**. 

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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I read with great interest the letter of Vojtek and Hoet. Well done and necessary. I have some remarks and suggestions: In the abstract the term "pre-approved" is not clear to all the readers. The exact date of approval would be useful because it could inform the readers that PHiD-CV has a long and great history.Page 2: "prequalified" is not clear (see above)Page 2 , second column, third line. I would add "evidence based" before "informed choice" in order to stress the big amount of available rigorous data.Page 2, 11th line: I would say "proves its **beneficial** impact..."It should be underlined that PHiD-CV is approved for use in children younger  than  5 years of age (that could be one the reason why it was not quoted in the paper of Feldam which focuses mostly on adult/elderly patients)In the table I would add "schedule" before "3+1"  or "2+1" . In the current version one may read "minus 3 plus 1" and may misunderstand.  

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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